The CORMAC study is now closed and the final core outcome set is published in Lancet Gastroenterology and Hepatology
We are working to improve anal cancer research.
Treatment for anal cancer can cause short and long term side effects. These side effects can affect quality of life.
Studies for new treatments should tell doctors how well a treatment works. They should also tell them how side effects affect quality life. In the past, studies have all used different ways of measuring the effects of treatment (outcomes). This makes comparing the results of trials very difficult. Trials have also been poor at reporting side effects of treatment and how treatment affects quality of life.
How we are helping
The aim of the CORMAC project is to agree a ‘core outcome set’ This is a list of outcomes that all trials in anal cancer should measure and report. Having a core outcome set will help to make sure that the results from all trials can be combined to get a better understanding of which treatments are best. It will also help to ensure that outcomes such as side effects and quality of life are included in research studies.
To agree which outcomes should be included in the core outcome set, we conducted an anonymous, international, online questionnaire (Delphi process), involving healthcare professionals and patients, followed by a joint health care professional and patient face-0to-face consensus meeting.
The study has now been completed. The final core outcome set is published in Lancet Gastroenterology and Hepatology. A summary of the project and the final core outcome set is shown in the infographic below:
For more information see our ‘Further Information and FAQs‘ section
This website presents independent research funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-1013-32064). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.